A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?
Open Access
- 1 November 2020
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (11), 2504-2506
- https://doi.org/10.3324/haematol.2020.261073
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Analysis of DC Functions Using CD205-DTR Knock-In MiceMethods in Molecular Biology, 2016
- pH-dependent recognition of apoptotic and necrotic cells by the human dendritic cell receptor DEC205Proceedings of the National Academy of Sciences of the United States of America, 2015
- A New Initiative on Precision MedicineThe New England Journal of Medicine, 2015
- Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesJournal of Hematology & Oncology, 2014
- Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failureLeukemia & Lymphoma, 2012
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed TherapyJournal of Clinical Oncology, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasThe New England Journal of Medicine, 2010
- Altered expression and endocytic function of CD205 in human dendritic cells, and detection of a CD205–DCL‐1 fusion protein upon dendritic cell maturationImmunology, 2006
- Expression of human DEC-205 (CD205) multilectin receptor on leukocytesInternational Immunology, 2006
- Hodgkin's Lymphoma Cell Lines Express a Fusion Protein Encoded by Intergenically Spliced mRNA for the Multilectin Receptor DEC-205 (CD205) and a Novel C-type Lectin Receptor DCL-1Online Journal of Public Health Informatics, 2003